Anti-CD 16 / CD 30 Bispecific Antibody Treatment for Hodgkin ’ s Disease : Role of Infusion Schedule and Costimulation with Cytokines 1

@inproceedings{Hartmann2001AntiCD1,
  title={Anti-CD 16 / CD 30 Bispecific Antibody Treatment for Hodgkin ’ s Disease : Role of Infusion Schedule and Costimulation with Cytokines 1},
  author={Frank Hartmann and Christoph Renner and Wolfram Jung and L{\'i}gia Rodrigues Silv{\'e}rio da Costa and Sandra Tembrink and Gerhard Held and Alexandra Sek and Jochen Koenig and Stefan Bauer and Michael Kloft and Michael Pfreundschuh},
  year={2001}
}
The natural killer cell-activating anti-CD16/CD30 bispecific monoclonal antibody (BiMAb) had shown efficacy in a Phase I/II trial of refractory Hodgkin’s disease (HD). To gain additional information on clinical efficacy and to investigate the effects of different application schedules and the concomitant application of cytokines, we performed a second randomized pilot trial using this BiMAb in patients with refractory HD. Patients received 43 25 mg HRS-3/A9 either as a continuous infusion for 4… CONTINUE READING